Bayer Ag S/Adr

Good afternoon and good morning everyone and welcome to our conference call to discuss Bayer's second quarter 2026 results. Bill will begin by sharing his perspective on the key achievements of the past few weeks and our path forward and we are delighted today to have Judith with us for a first quarterly earnings call. She will offer her initial perspectives and provide further insights into business performance and the outlook. Following the prepared remarks, we will open the call for Q&A and our three divisional presidents will join Bill and Judith then to address your questions. Before we get started, I would also like to encourage you to join our crop science field event on September the 2nd in Iowa. If you have any questions regarding registration or logistics, please reach out to our investor relations team. As always, please note the cautionary language in our safe harbor statement. And with that, over to you, Bill.

Hey, thanks, Jost, and hi, everyone. And by the way, I think most of you know this is Jost's last time leading the call before he runs off to lead the radiology business, so we'll try to make it a good one. But the past 90 days have been really important for Bayer, and operationally, we're on track for the year. We've made decisive progress on our long-term strategic priorities, and we're going to cover both of those things today. So let's start with the performance in the first half of 26. Across the group, our businesses are delivering what we committed. Sales are at 24 billion euros, growing 3% on a currency and portfolio adjusted basis, which we'll refer to throughout the call today. Core EPS is at 3 euros and 66 cents, which is also up 3% from our last year at this time. Our free cash flow in the first half is at negative 2.7 billion euros. This compares with negative 1.4 billion euros last year at this point, and it's due to the litigation-related payouts that we've previously communicated. So onto our businesses. CropScience delivered sales growth of 5.5%. This was driven by strong momentum in seeds and traits, including the additional licensing revenue we posted in the first quarter. EBITDA margin expanded to 31%, a considerable improvement over last year, reflecting higher margin sales, the licensing revenue I just mentioned, and disciplined execution. In pharma, we demonstrated continued resilience. Sales remained flat, with Nubeca and Corendia combining to grow 66%, overcoming significant and expected declines in Xarelto. ILEA is down 27%, driven by pressures from biosimilars, with the eight made business now representing half of our ILEA sales. The ENTRE continues to progress well and our base business is growing in part due to strong volume growth in radiology. Our EBITDA margin is at 26%. This puts us in line with expectations as we continue to invest in future growth in the second half of the year. Finally, Consumer Health posted growth of 3.5% with contributions from all but one category and particularly strong growth in nutritionals and dermatology. EBITDA margin is trailing prior year but on track to meet our outlook. Overall, we're pleased with our trajectory. Despite an uncertain environment, we're pacing well to meet our targets and we'll continue executing our plan. Team Bayer has what it takes to deliver. Now, I'll touch on our strategic priorities including some recent highlights. In pharma, we've received priority review for azindexin in both the U.S. and China, and we're preparing for a planned launch in the end of 26 or beginning of 27. Further, we closed the acquisition of perfused therapeutics, which we announced last quarter. This is a novel development medicine in glaucoma and diabetic retinopathy. CropScience continues to execute its five-year framework. and our efforts here are beginning to deliver tangible results as seen in the expansion of our margins. We're also optimizing our business setup. Last month, we consolidated our U.S. glyphosate business into Ruvion, a distinct entity that will be nimbler and better positioned in a commodity-driven market. Further, we continue to build our innovative portfolio. For instance, we announced a license agreement for broad commercialization of hybrid wheat One of the world's most important staple crops. Across the company, we continue to push for productivity gains with our operating model. Teams working on launches and pharma, driving profitability gains in crop science, and those making investment decisions in consumer health have much more ownership over their work. We think our lean entrepreneurial operating model positions us well to capitalize on the opportunities of artificial intelligence. And we're investing in AI. in both enterprise systems and tools for our people so that each person at Bayer can extend their productivity, making the greatest impact at the fastest pace and lowest cost. Finally, litigation. The last 90 days have been decisive in the company's years-long efforts to contain the litigation uncertainty. On June 25th, in Monsanto v. Dernell, the U.S. Supreme Court announced a landmark ruling for the cause of regulatory clarity, The decision was in no way ideological, with a majority of justices nominated by both Republicans and Democrats siding with the company. Further, the opinion was unequivocal. The Environmental Protection Agency is the authority when it comes to regulating crop protection products. Claims grounded in states' failure-to-warn theories are preempted and should be dismissed. Lower courts have already started acting on the Supreme Court's ruling. What does this decision mean for the company's multi-pronged strategy? The proposed class settlement between Monsanto and leading plaintiff's firms is moving ahead, and we remain convinced it is the best path to resolution, including for plaintiffs whose primary legal theory was deemed without merit by the nation's highest court. We're in a stronger position following the court's ruling. The final approval hearing in the state court in Missouri is now scheduled for August 19th, with a final decision expected later this year. During the interim, the company will participate in the class process, including briefing the court regarding objections and assessing the quality and quantity of opt-outs. On PCBs, as previously communicated, we aim to enforce the indemnity agreements Monsanto had in place. and there's a case moving forward now in federal court. Overall, our containment strategy is in a strong place with some important milestones ahead. We remain focused on making the right decisions for the company, both in the moment and for the long term. Over the past two and a half years, we've been laser focused on a clear set of priorities. Rejuvenating the pharma pipeline, significantly containing litigation, deleveraging, improving profitability at crop science, and making Bayer leaner, more dynamic and more productive. We've progressed in each of these five areas and each of them has demanded intense focus. And it's imperative that we maintain that focus. So we're concentrating on delivering our commitments and ensuring the best future for Bayer. So with that, I'll hand it over to Judith to walk you through the financials as well as her first impressions of the company. She's joined at a pivotal moment for Bayer and has been all in from day one. Judith, over to you.

Thank you, Bill, and welcome to everyone on the call. It's a pleasure to be with you here today. I'm delighted to have joined Bayer at such an exciting time. The team has made significant progress on litigation, and we remain firmly focused on containing the overhang. The goal remains that Bayer is increasingly valued for the strength of its businesses, innovation, and its growth potential. Having spent my first month listening to customers, colleagues, and investors, the following themes stand out. First, Bayer's innovation engine is a fundamental competitive advantage. Our leadership positions are built on decades of R&D investments, delivering breakthrough innovation that farmers, patients, and consumers rely on. Our teams are committed to innovate for our mission. We have attractive growth opportunities ahead of us supported by powerful long-term trends. We have strong positions in large markets with growing and aging populations. Our new operating model has made us leaner and more customer focused. Third, our financial priorities are clear. To continue to strengthen the balance sheet, to improve productivity and cash generation, and to create flexibility to invest for future growth in next generation medicines, ag technologies and consumer health. While we've made good progress on the transformation, there's still important work ahead. I see a clear opportunity to build on the momentum with strong execution and financial discipline to deliver sustainable value. With that, let me turn to our financial results. Net sales increased by 3% to 24.3 billion euros in the first six months. In Q2, sales increased by 2% to 10.9 billion euros. EBITDA before special items rose 7% to 6.6 billion euros in the first half, including an increase of 2% to 2.1 billion euros in the second quarter. Foreign exchange effects were not a material headwind this quarter. Core earnings per share came in at €3.66 for the first six months. This is consistent with the underlying business seasonality and our expectations for the year. If you look at Q2 specifically, core EPS of $0.95 was 17% below prior year, given non-recurring benefits in taxes and the reconciliation result in 2025. Both items show a more normalized pattern this year. in line with our expectations. Let's move on to free cash flow. This year, material litigation-related payouts amounting to 2.5 billion euros in the first half drove the negative cash flow and explained the decline versus the prior year. For the second quarter, we saw higher incentive payouts compared to prior year. Finally, net financial debt remained rather stable with a slight increase to 33.6 billion euros compared to the second quarter of 2025. Compared to the end of the first quarter this year, net financial debt increased by 1.1 billion euros driven by litigation payouts, the profuse acquisition for our pharma business and foreign exchange. In recent weeks, We successfully completed two important financing transactions. The €3 billion equity investment from Apollo marks an important strategic milestone. It strengthens our capital structure and provides additional flexibility for future financing needs. Upon closing, it will reduce our net financial debt in the second half of the year. We have since successfully placed $5 billion in U.S. dollar bonds, further demonstrating our ability to access the capital markets. These achievements have been an important team effort, and I would like to sincerely thank all of our colleagues who contributed to this, and importantly, to our first half results. Overall, our performance puts us well on track to deliver our full year guidance. Let's now take a closer look at the performance of our businesses. For crop science, disciplined execution of our five-year framework drives growth and margin expansion. Here today, we saw sustained momentum across the seed and trades portfolio and improved profitability while core crop protection continued to face pressure. Overall, the strong first half reinforces our confidence in delivering full-year guidance Even a sales mix is expected to shift towards lower margin products in the second half. In the second quarter, net sales grew 4% to 4.9 billion euros, driven by strong seed and trades performance and improved glyphosate volumes and pricing. Soybean sales exceeded expectations with 17% growth for the quarter. driven strong North America performance, including higher prices from the return of the dicamba label in the US. Soy growth reached nearly 70% year to date, or 13% excluding licensing income. In the second half, we expect lower excess seed sales in the United States due to improved utilization rates. Additionally, our transition from Intacta Roundup Ready 2 Pro to impact the two extend is expected to weigh on Brazil sales. Cotton also benefited from return of the Decamba label, driving both volumes and prices as expected for the quarter and contributing to 9% year-to-date growth. Other seeds and trades grew 21% for the quarter on solid canola expansion, growing 63% year-to-date. Following the strong Q1, Corn declined by 3% in the second quarter. It includes the anticipated phasing impact in North America, partly compensated by double digit growth in EMEA and APAC. For the first half, the business grew 4% with strong growth across all regions, despite reduced acres in the US. Corn crop protection declined 2% in the second quarter, driven by lower prices. The expected volume recovery was muted by dry weather, mainly in parts of Europe. The temporary reintroduction of Movento in France drove insecticide growth in the second quarter. Year to date, core crop protection declined 5% from ongoing generic pressure and portfolio pruning impacts. We expect growth in the second half of the year, supported by higher volumes. However, continued regulatory and pricing headwinds are anticipated to weigh on performance. Glyphosate sales recovered this quarter with higher pricing and increased volumes contributing to a 13% increase. A price spike in the second quarter nearly offset volume decline from the first quarter leaving glyphosate broadly flat over the first half of the year. On profitability, EBITDA before special items of approximately 900 million euros came in 30% higher than prior year, resulting in a margin of 18.4 in the second quarter. In addition to higher seed and trade sales, the strong execution of our five-year framework contributes to low margin exits in core crop protection, as well as COGS efficiencies. Furthermore, we benefited from insurance income and divestment gains. Year to date, EBITDA before special items margin of 31.4% is expected to moderate in the second half. This also includes a different distribution of licensing resolution income, which was realized in the first quarter this year compared to the fourth quarter last year, as well as pricing pressure and the impact from the Middle East war. Our pharmaceuticals business continues with solid delivery against its strategic priorities. This is clearly shown with strong growth of our new products and a solid base business contribution, which balanced the expected declines of Xarelto and ILEA. We're now at the inflection point of turning to growth going forward. While sales were in line with the prior year in the first six months, We expect to accelerate growth in the second half, putting us on track to achieve our full year outlook. For the second quarter, we achieved net sales of 4.5 billion euros, representing 1% growth versus the prior year period. Our key growth drivers continued their strong momentum. Nubeca grew by 64% in Q2 across regions, while Carendia sales increased by 83%, mainly driven by the US and China. With combined sales of more than 2 billion euros for the half year, and based on the current dynamics, we are well-proficient to meet the market expectations for the full year. On our new launches, performance of LinkWit and Biontra continues to be in line or even above our expectations. and we're continuing to drive launches in additional markets throughout 2026 and beyond. Xarelto and ILEA declined by 42 and 33% in Q2 effectively, driven by the expected effects of loss of exclusivity and biosimilar competition. While both declines were modestly above our guidance range, this was against the stronger prior year comparison. For the second half, we expect a softer comparison base. Importantly, ILEA 8mg continues to see strong uptake reaching around 55% of franchise sales in the second quarter and remaining on track for about 70% share by year end. Our base business grew 4% in the second quarter with continued strength in radiology and women's health more than offsetting volume-based procurement related impact on Asprin Cardio and Stevarga in China, as well as declined across other parts of our mature portfolio. For the first half, base business growth was 1% and we foresee broadly stable performance going forward. EBITDA before special items was down by 4% to 1.1 billion euros in Q2. resulting in a margin of 23.7%. The year-on-year decline was mainly driven by our decision to increase growth investments as well as pricing pressures partially compensated by higher volumes, a write-back for inventory and continued savings from efficiency programs. While our margin for the first half of the year was 26.4%, we will continue to invest into growth going forward and expect to end the year in line with our guidance. Turning to consumer health, we continue to focus on driving sustainable growth while navigating a volatile market environment, particularly in the United States, where consumer sentiment remains up to. Against this backdrop, net sales increased by 1.5% in the second quarter and 3.5% in the first six months. With that, we remain well-positioned to deliver within our full-year guidance range. Growth was driven by all non-seasonal categories, highlighting the strength of our balanced portfolio, strong category of positions, and focused investments. E-commerce continued to be an important growth driver, reflecting our investments in digital capabilities, and our ability to adapt to evolving consumer purchasing behaviors across channels. In nutritionals, brands such as Natural Elements and Elevit delivered strong online growth. These favorable sales dynamics helped offset the decline in allergy and cold reflecting softer seasonal demand as well as the pull forward of customer orders in the first quarter due to timing of seasonal orders in allergy as previously highlighted. Turning to profitability, the EBITDA margin before special items was 22.1% in the second quarter and 22.3% in the first half of the year. Benefits from our new operating model and ongoing cost efficiencies continue to support profitability while targeted investments in brands, innovation and digital capabilities are positioning the business for future growth. Foreign exchange headwinds impacted the first half year margin by about 50 basis points. Excluding these profitability remained broadly in line with the prior year and within our full year guidance corridor. Onto our outlook for 2026. We reiterate our group outlook on sales, earnings, and free cash flow at constant currencies for the full year 2026. Our outlook reflects the strong performance in the first half, but also the anticipated dynamics for the remainder of the year. In addition, we remain mindful of the dynamic external environment. On net financial debt, we have reflected the minority equity investment by Apollo with closing expected in the second half of this year. With that, we now anticipate net financial debt in the range of 29 to 30 billion euros down from previously guided 32 to 33 billion euros. Overall, we currently see a balanced risk and opportunity profile for our full year outlook, which continues to include our latest assessments on several external factors and geopolitics. Looking ahead, we continue to closely follow several key topics that remain fluid. For crop science, we continue to monitor geopolitical and weather-related developments, including potential El Nino impacts, whether volatility could affect planting and yields in some regions, and our technology-based seed and crop protection solutions are helping growers to manage these challenges. For our pharma business, We do not expect tariffs to materially affect our outlook this year. At the same time, we remain focused on developments in global drug pricing, particularly around MFN policies, and continue to evaluate the potential implications for our pricing and launch strategies. For consumer health, key variables in the second half of the year remain the trajectory of the consumer sentiment in the US and other key markets, The performance of seasonal categories and developments in the macroeconomic environment. Finally, on foreign exchange rates, in line with our practice, we have updated the foreign exchange estimate based on June month end spot rates. Compared to constant currencies, this leads to slightly lower headwind, the net sales, and to core earnings per share compared to the last estimate. And with that, over to you, Jost, for the Q&A.

Thank you very much Judith. Thank you very much Bill. We will now begin the Q&A session. Before we start, just a few housekeeping comments. If you have a question, please raise your hand and follow the instructions provided in the chat. To allow as many participants as possible to join, please limit yourself to two questions. First question today comes from Richard Foster from JP Morgan. He is followed by Sachin Jain from Bank of America. Richard, please go ahead.

Thanks Jost. A couple of questions please. First question on pharma. Obviously you pointed to the Biontra launch being relatively strong. We've seen the CardioTransforms trial failing for a potential competitor there. So just what's your thoughts on the changing environment for Biontra? How do you see potential going forward in terms of maybe peak sales and Should we anticipate Bientra sales being disclosed in Q3 this year? And then one question on crop. Maybe just one question on soy. If you could give us a little bit more color on the dynamics going forward into the Latin America season, but also how your market share has developed with the return of Dicamba and how we should think about potential further market share gains in coming seasons, maybe with Verconic. Thanks very much.

Hi, Richard, and thanks for the question on Biontra. So we're extremely pleased with the uptake. Obviously, the competitive environment is something that we're closely monitoring. We believe that The stabilizers as a group has proven clinical efficacy and this is the standard that people have to go against and we have clearly the strongest data set in that class with over 90% stabilization. Can we expect to report out BioNTRA in the third quarter? So I hope so. Certainly I expect to report out BioNTRA sometime in the second half of this year. Over to Rodrigo.

Thank you, Stefan. And thank you, Richard, for the question. And it's an important one for soybean, both in Latin America and North America. So let me start with the Latin America because it's an important one. Before I go to the details here, I just want to highlight this is very in line with our five-year framework. If you go back on the May 13 last year and you take the slide of soybean, what is happening right now is very in line with the plans that we have for the soybean. And what is that? So, Latin America first, and I'll invest a little bit of time here to share a little bit. Latin America, we are making a technology transition there. We have Intacta, as said by Judith, for the last many years, but Intacta is coming Thank you very much. and of course naturally right now you have less varieties being launched because of the patent expiration in the coming years. So we do expect, and that's the impact on sales that we predicted, the lower penetration of Intacta. But at the same time, and that's very important, Intacta 2 extends, we launch it and we are growing again double digits again. coming to 40% penetration while our competitor is low-digit still. So 40% penetration with Intacta to extend over 50 million acres with that new technology. And this is just the preparing for the launch of Intacta 5 Plus that will come in the next years. And this is also very aligned to the North America. When we planned for the soybean, we planned 27 and 28 as being transition years because of what I just mentioned in Latin America. as well for North America. North America is great to have the label back and to be able to grow the soybean in North America in the first six months by 13%, excluding the licensing agreement. But it's even more important as they prepare for the launch of Viconic, as you mentioned. And this is coming in the coming years for soybeans. So soybean overall, we are in a transition period, technology transition in Latin America, the preparation of the launch of Viconic. But if you think about the next five years, we are planning to grow soybean, especially in North America, but also with the new launches in Latin America. So thank you for the question because it allows me to go a little bit deeper on the soybean dynamics. Again, very aligned to what we shared before on the five-year plan that we have.

Great. Following from Sachin, we have Charles Pittman King from Barclays in line. But Sachin, you're first. Please go ahead.

and Sasha James from Bank of America. And firstly, I'd just like to reiterate what Bill said, that your sanctity helps you through what's been a volatile period and best of luck in your new role. And to my questions, big picture for Bill, you comment on the why is that you're open mind to group structure. So I want you to just provide a bit more color on your latest thought process and what could trigger a formal strategic review. Secondly, you referenced August the 19th. Could you just clarify whether you expect to communicate where your opt-in is at relative to threshold and I'm assuming you have a high-level view already. I wonder if you could share any color. And then I wonder, Jost, if I could just squeeze in a third. So, Asmodexian for Stefan. Factors to think about regarding the launch trajectory of this in terms of physician excitement, hospital formularies. And then I wonder if you could comment on pricing, given you most likely have to price this now, Creazom or Vexion AF data. And Judith referenced MFN thoughts in her introductory comments. Thank you.

Thanks Seijin. Regarding the question about the kind of group strategy and group structure, I think we've got a group here, the Board of Management, five of the six of us are here today and we think about this a lot because The key question for us is what's the most effective way to pursue our mission and also to secure the future of the company, which as you know was no trivial matter over the last few years with some of the challenges we faced. We're thinking about this all the time. We're definitely in a better position now than we've been at any point in the last few years to make strategic choices. But we still have these five key priorities. And if you think about them, we have the pharma continuing to make progress and invest there. We've done a good job rebuilding the late stage pipeline, but we got more work to do on the mid stage pipeline. In crop science, we've begun the work of improving profitability, but we've got more to deliver there. And that's a five year We've also got these things like the debt that we've demonstrated the ability to pay it down, but the balance sheet isn't yet where we want it to be. We're making progress, but again, more work to do there. Litigation is a topic, again, good progress, but we got to close the door. and finally this question of bureaucracy. I mean I think certainly three years ago we believed that bureaucracy was a significant even additional burden on Bayer compared to some of our peer companies. I think what we've done now with the progress we've made, the radical change in our operating model, we actually have an asset here but we've got momentum. We're getting basically better every quarter and we don't want to break that up right at the moment. I would say we've been very disciplined on these five topics and we remain very disciplined on that. As a leadership group, we have our heads up and we're thinking about what other options are there, what opportunities are there, and we're always thinking about that. But from where we look right now, we think our best option today is to basically keep driving home on these five topics so that we believe basically Improvements and continued improvements on these five areas will make our future better, whatever we decide to do structurally in the future, whether we're staying together as one Bayer or whether we do something different with a division. In any case, a better balance sheet, having clarity on litigation, more efficient, high-performing operating model, you know, stronger pharma division, stronger crop science division. These are all kind of no regret moves. And so we believe at least right now, we want to stay focused on that and keep moving forward. And, you know, I think we'll know when we see an opportunity, we'll talk about that and we'll make sure you're the first to know, Sachin. So, but meanwhile, we're going to keep our heads down and keep focused. Regarding August 19th, That's the scheduled date for the fairness hearing. It's a, yeah, it's an interesting time because, you know, obviously it's not a normal thing that happens in a class proceeding that you have a Supreme Court ruling that happens. Obviously this one's very much to our favor. So as I said, we're evaluating kind of the quantity and quality of outstanding claims or the people who opted out. As you can imagine, if people want to come back in, Just like there was a process to opt out that involves paperwork and all that sort of thing, to reverse that also requires paperwork, and that can be a bit cumbersome. So we're working on all that. I wouldn't expect that we're going to share anything about it until, yeah, basically until it's over, until we've got a final number, we've had a fairness hearing, and so we'll Yeah, we'll update folks when there's something concrete to update on, but as it stands, we're pleased with how that's going, and we keep moving forward. Stefan, you want to talk about azindexium?

Yeah, sure. Hi, Sachin, so thanks for the question, and I think we all share the excitement around We're getting ready to get this into the marketplace in the fourth quarter. Let me reiterate, this is a product that we believe is going to establish a new standard of care in the treatment of secondary prevention of secondary strokes. In terms of the trajectory, given that this is a A truly new game in town. On the one hand, we need to educate physicians. On the other hand, I do expect that physicians are going to broadly welcome and are going to start prescribing especially in the acute setting in the beginning as we launch. So we're getting ready for that. Of course, the limiting factor, as usual, is access. So that's the only thing that's going to probably slow things a little bit down. But I would hope that we see a slightly improved access versus normal cardiovascular launches as we've seen them like with Corendia, for example. On the pricing topic, we're pricing on the back of very, very strong clinical evidence which gives strong value for our product. I think many people were surprised by the strong showing both on efficacy but also on this immaculate safety that adds no additional bleeding versus given anti-platelet therapy. So we will be starting to price in the U.S. and in China and Europe will come next. So MFN considerations are more for sometime next year. In the meantime, let me be very clear. We're making the point today already with reimbursement entities across those geographies that are being looked into as a comparator for MFN that we will need to have comparable pricing. And if that is not the case, that will or that may create delays in access. So that's going to be an interesting battle to fight, but I think we're very clear on this. It's not going to be a pushover in those markets where we would follow the US launch sometime in 2027.

Excellent. After we hear Charles from Barks Days, we have Matthew Weston from UBS in the line. Charles, you go first.

Thank you for your help and wish you the best for the next role. Two questions for me, firstly on crop. Just thinking about, in terms of the glyphosate mix, could you provide any details around the price and volume growth breakdown for your glyphosate and non-glyphosate based herbicides? Just thinking about the FY26 volumes, you noticed in the early remarks that Global's launch remains stable, implying a 2H volume increase. Can we interpret this? Are you messaging that you think the global uncertainty has worsened? If you could also touch on whether or not you're considering El Nino as a tail or a headwind in this, and maybe just more broadly what your typical guidance philosophy looks like. Thank you.

Let's see. Rodrigo, could you hear? The sound was a little rough, but could you hear that all right?

Yeah, I think so, Bill. And Charles, I'll answer here because the sound here, but if I don't reach your point here, please let me know. But on the glyphosate question that you made, so let me go a little bit of the dynamics that we have, right? So Q1 started a little bit soft on glyphosate, then we had a price increase globally on glyphosate, and we had a recover that was mentioned by Judith on Q2. But glyphosate is a very dynamic business, right? We were, some weeks ago, we were on zero tariff for the U.S. import of China. We just recently had a resolution now that you had another tariff for importing from China to the U.S. And this is one of the key elements of how we are managing glyphosate. Different from our core protection or our seeds and trays, This is a commodity market that you really need to manage very agile. Pricing dynamics and adjustments that you need to do is almost like in a monthly basis. And this is one of the core concepts that we designed when we put the Glycosate team to operate as a unit here to really make that business as agile as possible. Bringing this to the business for this year, what we have today, on the first six months and the next six months gives us confidence that we're going to be on the guidance that we have for glyphosate. We're going to be monitoring right now, of course, the dynamic of global pricing. I mentioned about the tariffs in U.S., but also we're going to see that in the global dynamics. But I feel that we have an opportunity, and of course, clearly, if you have a tariff in U.S., brings an opportunity for our business in U.S., and we're going to be capturing that with this model that I just mentioned. But this is a little bit of what we have for the year. And overall, you asked me about the sales. Again, overall, Glyphosate business represents 10% of our total sales, just to give you a little bit of a range here that we have. But that should be helping us to deliver what we have planned for the full year. With that, Judith, back to you.

Yes. Thank you, Rodrigo, and thank you, Charles, for the question. There was indeed about a 200 million beat on crop science in the first half and Rodrigo has just gone through again and I did in my prepared remarks on what are some of the standout topics here. We also see though in the second half, but first of all the seasonality such as the first half is much bigger and so bigger opportunity there too and the second half in crop science we see a mixed change, so higher crop protection with a lower margin than the seed business. And indeed we planned in for potential to see if there's any, it's not without risk, let's just put it that way, versus the full year. And so that's why we are confident of confirming. If you ask me about the philosophy of how I look at guidance, It is our best knowledge, needless to say, but it's also one where we are very committed to, and so you have our commitment that we will meet this guidance. Maybe one last topic, even though it's smaller, when I had mentioned There were some positives in there that might not, that will not repeat in the second half. They're smaller of nature, but we mentioned divestment, we mentioned some insurance, and that's what, maybe 20% of the 200. Much, much smaller. I just want to give credit where credit belongs. It really has been an operational feat.

Thank you so much. Super, fantastic. So following Matt from UBS, we'll hear from James Quigley from Goldman Sachs. But Matt, go to the next one in line, please go ahead.

Thank you, Jost. Two questions for Judith, please. The first on the LARP transaction, is there any additional color you can give us so we can get our models right when we get the consolidation as to where we can land on a percent ownership, but more importantly, the profitability of LARP? and if you're not prepared to give us a number, can you help us out with relative to that 25% around for pharma, I assume it's a meaningfully more profitable business with no R&D burden, that some help would be great to get that minority in our model more accurate. And then the second question is more of a medium-term one. Stronger cash generation, a number of moves to reinforce the balance sheet and a strong business outlook I think have been messages today. Investors have had an 11 cent dividend for the last three years, totally understandably as you rebuild the balance sheet through litigation. But when should investors think about a return to a more normalized dividend payout from buyer? Is 2027 from 26 earnings too early? Or do we just have to wait and see?

Thank you for those questions. First on the Alarc Apollo transaction. We're not going to give details on exactly, so I think we're going to have to think about with the investor relations team on how we help you model this. I mean, I guess the way you have to think about it, on the one hand, we are selling equity, so that's an impact on our EPS. On the other hand, offsetting, partially offsetting is, of course, we have better access to debt at this stage, and clearly, you know, Proofpoint was the $5 billion that we were able to tap into right after the Apollo transaction. It's not very significant, but I hear your point. We're going to have to help you model this better. So stay tuned. On the dividend, indeed we had, given where the debt was, to pay minimum dividend over the last three years I think was the thing to do. We will, the right next time to come back to you on this question will be our total year results in February as we will work through our medium term plan. We will have a better view and that's the time that you should expect the communication around this.

And Judith, I wonder if you want to mention in the first part, because you mentioned about selling equity, but it'll show up. You said it'll show up in EPS, but it'll show up as the cost of the dividend, right, as opposed to a change in the share base or the equity base.

Yeah, exactly. It's a minority interest impact, absolutely.

So it'll show up on the P&L more as a, yeah, like a cost of capital. as opposed to like a deleting the share base.

Yeah, exactly.

I'm sure we can provide some estimate of what the future estimated EPS impact is or something.

Okay, great. So next is James from Goldman Sachs and he's followed by Joel Jackson from BMO. James?

Great, thank you for taking my questions, and again, thank you for all your help, Jost, and best of luck in the radiology business. The first question for me is for Judith, so thank you for laying out your initial impressions. From what you've seen so far and your experience in other companies, what are the key levers you can use to reduce the net debt? Are there any easy wins that you can implement from what you've seen so far, and how do you balance priorities here in terms of fixing the balance sheet versus investing in innovation, and then obviously reinstate the dividend as you've spoke to you before and are there any innovative ways like the Apollo deal that you can use to reduce the debt burden or to engineer flexibility to invest? and the second question is for Stefan. Investors are increasingly looking at the mid to long term outlook in pharma businesses, particularly with the patent coast in the mid 2030s that have been coming around the corner. You've closed Perfuse Pharma, but how are you thinking about organic versus inorganic investments and potential for more pharma deals versus some progress you've made with the pipeline as we've seen today. Nubeco and Coendia are launching very well. as we've seen, but investors will start to have one eye drifting towards the patent expirations. So how are you approaching this in the longer term? Thank you.

Yes, thank you, James. Very good question. Yeah, the way I look at it, so really coming into the company, I think there are very credible plans from the divisions on each improving their growth profile and their margin. I think the most obvious that you're going to see just because, you know, parts of the launches have already happened and you can see it with Nobeka and Carindia is, of course, in the pharma business as of the third quarter. But, you know, we're all working on this and all the different parts of the companies are going to be contributing. So once you have, you know, increasing results, You have reduced payouts also for litigation. Quite frankly, that's where I feel we will have good opportunity on both reducing the debt but also, of course, investing and potentially increasing the investments even into the future. and so I think we're in a good position to do both, deliver materially but also continue to invest into our businesses. The opportunity is there, we have the right teams and we're in the right markets.

Thanks, James. Needless to say that I love your question because I think your question states the obvious. We've really turned around. This farmer business and we're now already talking about the next success cycle because we sort of like taking this one for granted. Thank you for that. So when it comes to the post LOEE for Nobeka and Corendia, first of all, let me state we still have a couple of years to go before that really hits your models, but that's going to be still soon enough. So we're working obviously tirelessly to come up with the next success cycle, and that includes things like Perfuse, of course. It includes some of what we believe are truly interesting oncology medicines from our radiopharmaceutical platform, but also from Vividian. We're really advancing things fast on the immuno-oncology area side. We're also seeing potential still with higher risk, but still good potential from our cell and gene business. So we'll have some major readouts in the coming 12 months there as well, just as a reminder. We should in the first quarter read out our cardiovascular trial there with gene therapy in severe heart failure patients and a few smaller trials that are reading out so that will give us yes or no, some validation on these platforms. and we're advancing very nice on Bamden Apricel in Parkinson's as well, which is a phase three development asset. Add to that a few cardiovascular opportunities from our classic, let's say, research and early development platform and we need to up our game on deals. We're continuously doing deals, but you heard Judith, we're freeing up cash going forward because I'm so glad that we're starting to talk business and future and that should give us some ability to invest. We're not going to do major acquisitions. I don't think that's in the cards, but we're starting to beef up again also our external growth momentum in the years to come and I'm looking forward to that. Obviously, in order to get there, We need to first drive up Nubeka, Corendia, Asundexion, Biontra, Linquet to be really big products. I think we're well underway to doing so and that should give us headroom to do some of these investments that will be absolutely needed if we want to continue this nice success story that we've been building over the past few years. Thank you.

Excellent. Following Joel, we'll hear from Christian Seitz from Capital Chevreux. Joel, you're next.

Hi. Thanks for taking my question. I want to ask about if we look at what you're doing with Rubion and, you know, the other week you, they are, you know, looked at seeking countervailing duties against glyphosate in the U.S. and pulled that back quickly. There's some executive orders around elemental phosphorus and glyphosate. The first question would be if you could just give us an update on what the companies use on Arubian and Glyphosate, what that will do for Bayer, what your objectives are with everything you're doing on that side. And then my second question would be, and a little greedy here, but when you think of 2027 for crop science, do you think there's enough growth drivers at current crop prices to offset the one time, you know, uplift you've gotten with Glyphosate this year?

You know, Rodrigo, maybe I'll just comment on Ruvion at the high level and then you can talk about crop science and your outlook. I think it's really simple. There's nothing much more to say on this. We announced more than a year ago that we need to be able to run the glyphosate business differently because it's a very commoditized market and it needs really leanness, agility, and really fast adaptation to business conditions. And and so it didn't fit very well in our portfolio. So we've we've created a separate entity for that. And we're beyond that we're not really prepared to comment about, you know, future outlook. But that's, that's where we are today. And that's, that's where we'll be until further notice. Rodrigo, you want to talk about the Business Outlook. Sure.

Hey, Joe. Thanks for the question. A little bit early to go deeper on 2027. Of course, on Q3, we're going to talk more about that and a little bit of the dynamics. But high level, we continue to see momentum on our seeds and trades. I think I'm very pleased with the performance that we have on the seeds and trades over the first six We were able to grow corn volume on the first six months despite the area decreasing U.S. Also pricing as well. So we continue to see momentum on the seeds and traits and we are really preparing our safety business this year. We are doing some divestments and pruning some of the work that we have. So we're going to go into more details in 2027 in Q3. But I would say that very consistent to the plans that we have on our five year framework. We have that fast of innovation and some of the launches is starting in 27. But at the same time, another important element, we are already harvesting the start of all the savings that we are putting in place, but the savings will keep even further in 27, 28, 29 in our plan. So the combination of the innovation on the top line and the savings that we are putting aligns us with the five-year framework for the 27, but more details to come in Q3. Thank you.

Great, so next is Christian from Kepler Chevreux, and he's followed by Thibault Buterin from Morgan Stanley. Christian, go ahead.

Yes, hello Bill, Judith and Jost and team, and Judith, welcome. Jost, all the best for your new position. Two questions, please. Crop science. I'm a bit surprised by the robust organic growth in Europe, and I would believe Europe has a bit more crop protection than seeds versus the Americas. Given the severe drought we are seeing in large parts of Europe, are you concerned about inventory build-ups and how would you plan to manage this into the next season? And then my second question, actually also on crop, just modeling question. DNA has been all over the place in crop science in the past several quarters. What would you consider a normalized depreciation and amortization level in crop per year? Thanks very much.

Thank you, Christian. So let me jump here already on EMEA. So the first thing that I want to highlight, I'm very pleased with a double-digit growth in our seeds and traits in EMEA. That was a very important element, and we are growing the business there. We have some very cool highlights of the in some of the countries, like in Italy, and we continue to growing in some very key markets for us there. So double-digit growth in the seeds and traits. Inventory is in the same level that we had last year in overall EMEA. So I'm not, as you know, we manage sellout very close. So we don't do selling if we are not seeing a great movement in sellout. But you're right in terms of the weather impact. If you look to the fungicide sales that we have in the first six months, This was impacted by the weather in EMEA. It's very dry, so you probably have much less disease, and you may have less application of fungicides. So we see that, but we adjust our selling. So inventory-wise, to your specific question, I think we are under control. You have some spots that you're gonna have to manage but overall the inventory in EMEA is at the same level that we had last year so it's in a good place but also when you talk about the performance highlight for the citizen trades also the Movento extension in France that is also an important element of the performance of EMEA.

Yeah, I don't know who wants to cover the DNA. Maybe we'll come back on that one.

Okay, then we'll cover the DNA question later. First is a question from Thibault Boutara. Thibault, please go ahead.

Thank you. Thank you very much. Just a couple of questions on pharma. 8 mg, a very, you know, gross performance. Can you just remind us what's happening in terms of IT in Europe and your key countries Is there an IP protection on the DAOs? Or is it just a question of by similar, developing the same formulation to help us understand the shape of the 8-minute harm as it becomes more important? And then, the second question, you know, when do you feel like you would be ready to share potential data and potential new indications? Do you see a broad scope of potential indications as a mechanism, obviously, you know, work very, very well

Thank you Thibault and so yeah let me let me try to go one after the other first idea eight milligrams yes we're now more than half of our sales are eight milligrams That's very good to see. Unfortunately, the 2 mg is getting heavy fire, both on pricing, most importantly, but also obviously volume-wise now. So we're going to be landing inside of our guidance, but I would have wished for even some better results there. In terms of protection, we have limited protection for now on the 8 mg. It's something that we're working on, but we would have to see some product that would be in development and that in theory could enter the market. Asundaxion, obviously love that question. Please stay put a little bit longer. We're working on this. We see potential for more, but I don't want to give up some of our thinking because I think it's innovative thinking. that has not necessarily been explored to the same degree up to now. We took our learnings from the failed AF Oceanic Trial and tried to apply those learnings as we move forward, potentially exploring also other indications. But let's also not get sidetracked here. We have an incredible opportunity ahead of us. We're recreating a new standard of care, and I think the unmet need is extremely high. for stroke prevention. So a lot of good things to have, but rest assured, we will inform you in due time at the latest when we give our next R&D update about our ideas on anticoagulation. Thank you.

Excellent. We will now hear questions from Tony Jones from Roche, and he's followed by Alina Shamsi from Jefferies. Tony, close yours.

Thanks all, best of luck Jost and welcome Judith. I've got two quick ones left. Firstly for Bill, at the end of last year you told me that over half your time quite often was spent on litigation. That should be changed for the better. What are you going to spend more time on now as that time in litigation comes? Only a question for Judith. You mentioned in the presentation that cost savings

The first one was for Bill on litigation.

Last year you told me that you spend a lot of time on litigation. As that now may be coming to an end, how will you be reallocating your time for the rest of the year in N27? And then secondly for Judith, you talked about efficiency gains in the first half. Any indication what the total year gain could be and whether there'll be further benefits in N27? Thank you.

Thanks Tony, appreciate your curiosity about my schedule. I look forward to spending less time on litigation for sure and there's a number of interesting topics but I think probably the biggest one is working with this group on how we fully harness the power of our new operating model and the intersection of that with AI We have a lot. Thank you for joining us today. Less time on litigation and more time on that fundamental driving the mission forward and driving our performance forward.

And that almost answers the question I had too. Thank you, Tony, because Really, it is the new operating model that has brought most of the savings. It's less layers, it's also 90-day cycles, it's faster, but here there's more to come. You've heard at different points in time from the colleagues on all of the efforts that are ongoing to improve margins, and that's literally the case for all three divisions and enabling functions, if I may say so. And so, yes, there will be more to come and we will keep working on this. And while I have the mic, maybe I'll answer the question on the Christian's question on crop science DNA. So as a point of reference, we're not giving today data about 2027. But as a point of reference, in 2025, it was 2.8 billion. And in the first half, it was one and a half billion. So hopefully that helps you to model.

Fantastic. We have no more analysts in the line to ask further questions. So I thank you very much. As many of you know, this is my last quarter as head of investor relations, but I said it earlier and I look forward to working with the bioradiology team. It's been a great privilege, a pleasure and fun to engage with all of you over the years and I would really like to thank you a lot for the good discussions we had, the support and the continued interest in Bayer. Please continue to reach out to the investor relations team and take the opportunity to get to know my successor, Jana Ackermann. She's with us today. She's great and I'm very confident that you will be in the best hands. Thank you once more. And with that, we conclude our Q2 2026 Learning School. Have a great day.